Literature DB >> 15857728

Adoption of naltrexone to treat alcohol dependence.

Bret E Fuller1, Traci Rieckmann, Dennis McCarty, Kevin W Smith, Helen Levine.   

Abstract

Three surveys (1997, 1999, and 2001) of outpatient substance abuse treatment centers in Connecticut, Massachusetts, Rhode Island, Maine, Vermont, and New Hampshire examined organizational characteristics that influenced the adoption of naltrexone. Structural equation modeling with manifest variables assessed predictors related to the use of naltrexone. Use of naltrexone increased over time from 14% in 1997 to 25% in 2001. In 1997, programs funded by managed care were more likely, and clinics that provided only substance abuse services were less likely to use psychiatric medication and naltrexone. In subsequent years, counselor education level and organization size also influenced use of naltrexone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857728     DOI: 10.1016/j.jsat.2005.02.003

Source DB:  PubMed          Journal:  J Subst Abuse Treat        ISSN: 0740-5472


  35 in total

1.  The adoption of alcohol pharmacotherapies in the Clinical Trials Network: the influence of research network participation.

Authors:  Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2010-02-01

2.  Timing of buprenorphine adoption by privately funded substance abuse treatment programs: the role of institutional and resource-based interorganizational linkages.

Authors:  Sarah A Savage; Amanda J Abraham; Hannah K Knudsen; Tanja C Rothrauff; Paul M Roman
Journal:  J Subst Abuse Treat       Date:  2011-08-09

3.  The adoption of medications in substance abuse treatment: associations with organizational characteristics and technology clusters.

Authors:  Hannah K Knudsen; Lori J Ducharme; Paul M Roman
Journal:  Drug Alcohol Depend       Date:  2006-09-12       Impact factor: 4.492

4.  Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network.

Authors:  Lori J Ducharme; Hannah K Knudsen; Paul M Roman; J Aaron Johnson
Journal:  J Subst Abuse Treat       Date:  2007-02-22

5.  Empirically supported substance abuse treatment approaches: a survey of treatment providers' perspectives and practices.

Authors:  Diane M Herbeck; Yih-Ing Hser; Cheryl Teruya
Journal:  Addict Behav       Date:  2007-12-23       Impact factor: 3.913

6.  A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence.

Authors:  Helen M Pettinati; Kyle M Kampman; Kevin G Lynch; Hu Xie; Charles Dackis; Amanda R Rabinowitz; Charles P O'Brien
Journal:  Addict Behav       Date:  2007-11-17       Impact factor: 3.913

7.  Adoption and diffusion of evidence-based addiction medications in substance abuse treatment.

Authors:  Carolyn J Heinrich; Grant R Cummings
Journal:  Health Serv Res       Date:  2013-07-16       Impact factor: 3.402

8.  Disparities in access to physicians and medications for the treatment of substance use disorders between publicly and privately funded treatment programs in the United States.

Authors:  Amanda J Abraham; Hannah K Knudsen; Traci Rieckmann; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2013-03       Impact factor: 2.582

9.  Adoption of injectable naltrexone in U.S. substance use disorder treatment programs.

Authors:  Lydia Aletraris; Mary Bond Edmond; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2015-01       Impact factor: 2.582

10.  Counselor attitudes toward pharmacotherapies for alcohol dependence.

Authors:  Amanda J Abraham; Lori J Ducharme; Paul M Roman
Journal:  J Stud Alcohol Drugs       Date:  2009-07       Impact factor: 2.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.